Treatment Effect of Tofacitinib, Adalimumab Compared in RA
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, July 12, 2023 -- For adults with rheumatoid arthritis (RA), there is a modest reduction in the mean Disease Activity Score in 28 joints using C-reactive protein (DAS28-CRP) at three months for patients receiving tofacitinib (TOF) versus adalimumab (ADA), but there is no difference at nine months, according to a study published online June 29 in JAMA Network Open.
Claire T. Deakin, Ph.D., from OPAL Rheumatology Ltd. in Sydney, and colleagues emulated a randomized clinical trial comparing ADA and TOF in adults with RA who were new users of a biologic or targeted synthetic disease-modifying antirheumatic drug. Data were included for 842 patients: 569 treated with ADA (40 mg every 14 days) and 273 with TOF (10 mg daily).
The researchers found that at baseline, three months, and nine months, the mean DAS28-CRP was 5.3, 2.6, and 2.3, respectively, in the ADA group, and 5.3, 2.4, and 2.3, respectively, in the TOF group. The estimated average treatment effect for TOF versus ADA was −0.2 and −0.03 at three and nine months, respectively.
"The results of this observational study are consistent with clinical trial data and support the current European Alliance of Associations for Rheumatology treatment guidelines," the authors write.
Several authors disclosed ties to the pharmaceutical industry; one author is director of Software4Specialists.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
Rheumatology Workforce Increased 20 Percent From 2009 to 2019
THURSDAY, March 14, 2024 -- The overall number of clinically active rheumatology providers grew more than 20 percent during the last decade, according to a study published online...
Risk for Autoimmune Inflammatory Rheumatic Disease Increased After SARS-CoV-2
TUESDAY, March 5, 2024 -- Patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have an increased risk for incident autoimmune inflammatory...
Sinusitis Linked to Increased Risk for Subsequent Rheumatic Disease
WEDNESDAY, Feb. 28, 2024 -- A history of sinusitis is associated with an increased incidence of rheumatic disease, according to a study published online Feb. 27 in RMD...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.